EN | UA
EN | UA

Help Support

Back

Remdesivir proved to be promising in its early trial results

Remdesivir proved to be promising in its early trial results Remdesivir proved to be promising in its early trial results
Remdesivir proved to be promising in its early trial results Remdesivir proved to be promising in its early trial results

What's new?

Remdesivir showed faster recovery and better survival rates in COVID-19 patients as compared to placebo.

As per Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) the U.S. government trial on remdesivir safety and efficacy has shown a recovery rate 31% faster as compared to placebo, these are preliminary trial results and are highly significant. The experimental drug by Gilead Sciences Inc. (GILD.O) could become the standard of care for COVID-19 said, Dr Fauci. The FDA needs to be completely sure on the safety and efficacy of the drug even before granting emergency authorization. Out of 1,063 COVID-19 patients, the remdesivir group recovered in 11 days and placebo group required 15 days to recover. The patients in remdesivir showed a better survival rate than in the placebo group. The complete trial results are expected to be out by mid-May. Dr Aneesh Mehta, a researcher on the NIH trial from Emory University School of Medicine in Atlanta said that complete data will better clarify the outcomes.

Source:

Reuters

Article:

Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: